Beiersdorf, the renowned skincare giant based in Hamburg, has announced a significant stride in anti-aging research with the introduction of ‘Glycostop™,’ a patented active ingredient targeting glycation—a process that hastens skin aging due to sugar. This milestone represents the culmination of a decade-long research journey involving the evaluation of approximately 1,700 substances.
Glycation, a natural yet detrimental chemical reaction wherein sugar molecules bind with proteins, notably diminishes skin elasticity and resilience, thereby fostering wrinkles and a yellowish discoloration. Beiersdorf’s latest innovation, NAHP (N-Acetyl-L-hydroxyproline), acts decisively in thwarting the formation of harmful glycation end-products (AGEs) by up to 68%, thus safeguarding the integrity of the skin’s collagen and elastin fibers. The breakthrough owes its success to the leadership of Dr. Gitta Neufang and her team comprising over 1,000 researchers, leveraging Beiersdorf’s rich heritage of anti-aging breakthroughs such as coenzyme Q10.
This pioneering development not only enriches Beiersdorf’s anti-aging product range but also establishes new benchmarks in skincare technology. The unveiling of the NIVEA Q10 Dual Action Serum in April 2024, which amalgamates ‘Glycostop™’ with Q10, offers consumers a potent dual-action formulation addressing wrinkles and skin aging at their source. This product epitomizes the company’s dedication to sustainability, featuring eco-conscious packaging and a formulation devoid of harmful additives.
